Department of chemical sciences, National Institute of Pharmaceutical Education and Research (NIPER), Balanagar, Hyderabad, 500037, India.
Division of Molecular Microbiology and Immunology, CSIR-Central Drug Research Institute, Sector 10, Janakipuram Extension, Sitapur Road, Lucknow, 226031, UP, India.
Chem Biodivers. 2022 Jul;19(7):e202200324. doi: 10.1002/cbdv.202200324. Epub 2022 Jun 23.
In pursuit of potent anti-TB agents active against drug resistant tuberculosis (DR-TB), herein we report synthesis and bio-evaluation of a new series of isoxazole-carboxylic acid methyl ester based 2-substituted quinoline derivatives. Preliminary evaluation indicated selectivity towards Mtb H37Rv, with no inhibition of non-tubercular mycobacterial (NTM) & bacterial pathogen panel. Out of 36 synthesized compounds, majority exhibited substantial inhibition of Mtb H37Rv (MIC 0.5-8 μg/mL). Cell viability test against Vero cells revealed no significant cytotoxicity. Further, screening against drug resistant strains (DR-Mtb) found hit compound displaying promising potency (MIC 1-4 μg/mL). Structure optimization of the hit led to the identification of lead compound demonstrating potent inhibition of both drug-susceptible Mtb (MIC 0.12 μg/mL) and drug-resistant Mtb (MIC 0.25-0.5 μg/mL) along with a high selectivity index (SI) >80. Taken together, with appreciable selectivity and potent activity, these chemotypes show prospect to be turned into a potential anti-TB candidate.
为了寻找对耐药结核病(DR-TB)有活性的强效抗结核药物,我们在此报告了一系列基于异噁唑羧酸甲酯的 2-取代喹啉衍生物的合成和生物评价。初步评价表明,这些化合物对结核分枝杆菌 H37Rv 具有选择性,对非结核分枝杆菌(NTM)和细菌病原体无抑制作用。在所合成的 36 种化合物中,大多数对结核分枝杆菌 H37Rv 具有显著的抑制作用(MIC0.5-8μg/mL)。对 Vero 细胞的细胞活力测试显示没有明显的细胞毒性。此外,对耐药菌株(DR-Mtb)的筛选发现,候选化合物显示出有希望的活性(MIC1-4μg/mL)。对候选化合物进行结构优化,确定了先导化合物,该化合物对敏感型结核分枝杆菌(MIC0.12μg/mL)和耐药型结核分枝杆菌(MIC0.25-0.5μg/mL)均具有很强的抑制作用,且选择性指数(SI)>80。综上所述,这些化学型具有良好的选择性和强大的活性,有望成为一种有潜力的抗结核候选药物。